Find AMR Resources
Connecting the AMR community with the solutions it needs
The tools advancing the AMR response are as diverse as the problem itself, spanning contract services, diagnostics, surveillance platforms, infection prevention technologies, digital technologies, and beyond. This growing directory brings them together in one place, making it easier for researchers, clinicians, investors, and advocates to find, evaluate, and connect with the solutions the global AMR fight needs.
OGI Bio is an Oxford-based biotechnology company developing novel antimicrobial compounds derived from natural product scaffolds. Its research focuses on identifying and optimizing molecules with activity against drug-resistant Gram-negative bacteria , one of the most difficult and underfunded areas of AMR drug discovery , through a combination of natural product chemistry and medicinal chemistry optimization.
Omnicin Therapeutics is a London-based biopharmaceutical company developing novel antibiotics for drug-resistant Gram-negative infections. Its lead program targets carbapenem-resistant Enterobacteriaceae , among the WHO\'s most critical priority pathogens , using a new class of antibacterial compounds with a mechanism of action distinct from existing antibiotic classes, addressing the urgent clinical need for effective treatments against last-resort-resistant infections.
Omnilytics is a Salt Lake City-based company developing bacteriophage-based products for agricultural and food safety applications. Its phage-based biocontrol solutions target drug-resistant bacterial pathogens in food production environments , reducing antibiotic use in agriculture, one of the primary drivers of AMR , while providing effective alternatives to antibiotic treatments for bacterial disease control in livestock and food processing settings.
Founded in 2015 and headquartered in Jerusalem, Israel, Omnix Medical is a clinical-stage biopharmaceutical company developing novel antimicrobial peptides for life-threatening drug-resistant infections. Its lead compound OMN6, which has received FDA Fast Track designation, targets Acinetobacter baumannii by disrupting bacterial cell membranes , a mechanism effective regardless of resistance genotype and with a low risk of triggering new resistance.
Ondine Biomedical is a Vancouver-based life sciences company pioneering photodisinfection-based therapies for infection prevention and treatment. Its Steriwave nasal photodisinfection system , approved in Canada, Europe, and Australia , uses light-activated antimicrobial therapy to eliminate MRSA and other resistant pathogens from the nasal cavity before surgery, reducing post-surgical infections without contributing to antibiotic resistance.
Oppilotech is a drug discovery company using proprietary predictive computational modelling to simulate biological systems and generate high-resolution insights into disease mechanisms and potential therapeutic targets. Based in Pune, India, the company applies its platform to accelerate the identification and development of novel drug candidates, including for antimicrobial applications, reducing the time and cost of early-stage drug discovery.
Oppilotech have developed a proprietary High-Resolution Dynamic Modelling platform that produces detailed computational simulations of cellular processes which can then be compared to traditional wet-lab experiments in order to validate or question the accuracy of the computer model. This process can occur thousands of times in a machine learning cycle. The end result is a model which is accurate, reliable; reveals new biological processes and novel approaches for therapeutic interventions.
Oxford Silk Phage Technologies is an Oxford-based spinout developing bioactive textile devices that integrate bacteriophages into surgical implant materials and wound dressings. Its technology embeds multiple phage species into yarn structures to provide targeted, sustained bactericidal activity against drug-resistant pathogens , preventing surgical site infections and reducing antibiotic dependence in post-operative and wound care settings.
PACE , Pathways to Antimicrobial Clinical Efficacy , is a UK-based public-private partnership dedicated to accelerating the development of new diagnostics and treatments for AMR. Funded by Wellcome and UKRI, PACE provides clinical trial infrastructure, regulatory expertise, and development support for promising AMR candidates, specifically addressing the late-stage development bottlenecks that have caused multiple promising antibiotic programs to stall or fail.
Peptris Technologies is a Bengaluru-based AI-powered preclinical drug discovery company using its proprietary PepAI platform to accelerate the identification of novel therapeutic peptides. The company applies deep learning to design and optimize antimicrobial peptides and other biologic candidates targeting drug-resistant pathogens, recently securing Series A funding to advance its pipeline of AI-designed antibacterial agents.
Contract Development and Manufacturing providing access to complex technologies for small-molecule API synthesis, Sterile injectables fill-finish and Oral Solids.
Pharmafilter is a Dutch company providing integrated waste management and wastewater treatment solutions for hospitals and healthcare facilities. Its systems capture pharmaceutical residues , including antibiotics , directly at the point of care, preventing them from entering municipal wastewater systems and reducing the environmental drivers of antimicrobial resistance development in water bodies.
PhAST is a Lausanne-based diagnostics company developing rapid single-cell imaging technology for antimicrobial susceptibility testing. Its platform accelerates AST results from days to minutes by imaging individual bacterial cells in real time, enabling clinicians to identify effective antibiotic treatments at the start of care rather than relying on days-long culture-based methods.
As a company driven by its promise to patients, we are excited about our further collaboration with PreviPharma, which seeks to identify new plasma proteins for the treatment of diseases with high unmet medical need.
QuantBioRes is a Copenhagen-based biotechnology company applying computational quantum biology and molecular simulation to AMR drug discovery. Its platform uses physics-based modelling to understand resistance mechanisms at the atomic level , identifying novel drug targets and designing compounds that are less susceptible to known resistance mutations, offering a computationally driven approach to accelerating the discovery of resilient new antibiotics.
Quickfox Consulting is an Amsterdam-based technology consultancy specializing in robotic process automation and AI-driven workflow solutions for the life sciences and healthcare sectors. It supports AMR-related organizations in automating data management, regulatory reporting, and research workflows , helping pharmaceutical companies, diagnostic developers, and public health agencies improve operational efficiency in their AMR programs and data-intensive research pipelines.
We have a totally new way of approaching and solving the problems of Pathogens. A new and unique technology is available from QURES GROUP LTD, to counter a very wide range of these pathogens, . The following pages within this website describe the Problems caused by Pathogens, why and how we found our unique technology to overcome them, and where our abilities can benefit Humans and the Planet.
Agar is suplemented with azole drugs at specific concentrations. Based on presence or absence of growth azole-resistant, colonies can be identified.
RapidX Bio is a San Diego–based diagnostics company developing ultrafast disease detection technology for infectious diseases. Its platform aims to dramatically accelerate pathogen identification and antimicrobial susceptibility testing , providing clinicians with actionable diagnostic results in minutes rather than the hours or days required by conventional culture-based methods, supporting timely, targeted antibiotic prescribing decisions.
Resistell is a Swiss diagnostics company developing the world\'s fastest antibiotic susceptibility testing platform, using proprietary nanomotion technology to detect bacterial movement at the single-cell level. Its PhenoTech system delivers AST results in approximately two hours , far faster than culture-based methods , without requiring bacterial growth, providing clinicians with actionable resistance data at the start of treatment.
Stay connected so that you don't miss the latest AMR insights and updates.
